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Tissue-specific exon discovery <p>Comprehensive exon microarrays with a simple intra-gene normalization algorithm were used to detect human tissue-specific alterna- tive splicing events, suggesting significant expression outside of known exons and well annotated genes and a high frequency of alternative  splicing events.</p>
Abstract
Background: Higher eukaryotes express a diverse population of messenger RNAs generated by
alternative splicing. Large-scale methods for monitoring gene expression must adapt in order to
accurately detect the transcript variation generated by this splicing.
Results: We have designed a high-density oligonucleotide microarray with probesets for more
than one million annotated and predicted exons in the human genome. Using these arrays and a
simple algorithm that normalizes exon signal to signal from the gene as a whole, we have identified
tissue-specific exons from a panel of 16 different normal adult tissues. RT-PCR validation confirms
approximately 86% of the predicted tissue-enriched probesets. Pair-wise comparisons between the
tissues suggest that as many as 73% of detected genes are differentially alternatively spliced. We
also demonstrate how an inclusive exon microarray can be used to discover novel alternative
splicing events. As examples, 17 new tissue-specific exons from 11 genes were validated by RT-PCR
and sequencing.
Conclusion:  In conjunction with a conceptually simple algorithm, comprehensive exon
microarrays can detect tissue-specific alternative splicing events. Our data suggest significant
expression outside of known exons and well annotated genes and a high frequency of alternative
splicing events. In addition, we identified and validated a number of novel exons with tissue-specific
splicing patterns. The tissue map data will likely serve as a valuable source of information on the
regulation of alternative splicing.
Background
Alternative splicing dramatically expands the protein coding
potential of higher eukaryotes. Current estimates suggest that
greater than 60% of human genes have more than one iso-
form. The expression of specific transcripts is regulated in
developmentally and tissue-specific manners (reviewed in
[1]). Alternatively spliced isoforms from the same gene can
produce proteins with different properties and distinct func-
tions. In one example, two mRNAs transcribed from the bcl-
x gene that utilize different 5' splice sites result in proteins
that have antagonistic functions. The short form of bcl-x pro-
motes apoptosis, while the long form inhibits cell death [2].
Errors in mRNA processing have been associated with cancer
and other human diseases [3]. It has been estimated that 15%
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of disease-causing point mutations in humans affect
sequences that regulate splicing [4]. In the pharmaceutical
industry, alternative splicing is often overlooked but could be
important to drug discovery programs. New targets previ-
ously missed, or additional isoforms of existing drug targets
could be discovered, thereby increasing the pool of targets for
new drug screening. Valuable information can be obtained by
studying the levels of individual transcripts. It is possible that
previously unknown or unstudied transcript variants for
genes could provide new insight into biological function or
provide new targets for mechanism of action studies and drug
development. Current large-scale methods for monitoring
expression must evolve to take into consideration the rich-
ness of transcript variation.
Much of what is currently known about the mechanism and
regulation of splicing has come from research of a relatively
small number of splicing reporter constructs and a handful of
regulated exons [1]. While this focused approach has been ini-
tially informative, it is not yet clear if it will generalize to other
splicing events or the splicing apparatus as a whole. Because
of differences in context and surrounding sequence each
splicing event is essentially unique. With so many unique
events, the ability to study the splicing of many events in par-
allel should provide valuable insight into the mechanism of
splicing and the regulation of alternative splicing.
To date, most of the studies of genome-wide alternative splic-
ing have relied on predictions of splicing events based on
expressed sequence tag (EST) or mRNA sequences [5,6].
However, using ESTs to study splicing poses several chal-
lenges, including a bias towards the ends of transcripts, poor
coverage of many tissue types, differences in library construc-
tion protocols, and poor representation of low abundance
transcripts [7]. In addition, some EST libraries also contain
poor quality sequence, genomic contamination, and mis-
spliced RNAs, which can confound the results. While efforts
have been made to estimate expression patterns and find tis-
sue-specific splicing events using EST frequency and library
source information [8-10], the examination of EST sequences
is not ideal for studying alternative splicing. Furthermore, it
is not practical to extend sequencing based approaches to
cover all tissues, disease states, and stages of development.
DNA microarrays have proven to be a powerful tool for profil-
ing the expression levels of many genes in a single experiment
[11,12]. In addition, several different approaches using micro-
arrays to monitor splicing events have been used successfully
[7,13-17]. Probes that span exon-exon junctions can discrimi-
nate between isoforms and provide useful information about
how exons are joined together. However, since these arrays
are typically designed based on observed sequences, junction
microarrays are not optimal for discovery of novel isoforms.
Several recent studies have shown that a much larger than
anticipated fraction of the human genome is transcribed [18-
21]. Therefore, it is likely that the current set of annotated
exons is incomplete.
In order to create a tool with a higher likelihood of discover-
ing previously unknown transcript variation and content, we
have designed a high density oligonucleotide microarray that
contains probes for every predicted exon in the human
genome. This design uses a combination of gene annotations,
sequence information, and gene prediction algorithms as
content sources. The design includes four probe pairs (perfect
match and single base-pair mismatch) for more than one mil-
lion predicted exon clusters (groups of overlapping exons).
More than 9.6 million unique probes were manufactured
onto a 4 chip set using a light-directed in situ DNA synthesis
approach [22,23]. In order to evaluate transcript variation
broadly across the genome and the human body, we hybrid-
ized target generated from three biological replicates of six-
teen normal adult human tissues, including six sub-regions of
the central nervous system.
Using a simple algorithm that normalizes the intensity of each
probeset by the overall expression level of the gene the
probeset maps to, we identified exons that are specifically
enriched in one tissue or a group of tissues. Since the brain is
known to be rich in alternative splicing [10,24,25], we focused
our analysis on alternatively spliced regions that had statisti-
cally different inclusion rates in the six brain tissues as com-
pared to the remaining non-brain tissues. Many of the
alternatively spliced regions identified as brain enriched were
validated by RT-PCR. In doing so, we identified several new
splicing patterns that were not represented in the publicly
available sequence data. Furthermore, we discovered several
novel exons that demonstrated tissue-specific splicing pat-
terns. The novel exons have probesets on the array due solely
to computational prediction and lack support from any cDNA
sequence data. Our results suggest that calculations of the fre-
quency of alternative splicing based on cDNA sequence infor-
mation alone are likely to be an underestimate.
Results
Array design
The arrays in the set represent a prototype human exon array
and were designed to measure the expression levels of exons
as independent objects. The goal of the design was to be as
inclusive as possible when selecting content using a combina-
tion of exons that have been identified by empirical observa-
tion as well as exons derived from computational prediction
across the entire human genome. The combination of pre-
dicted and confirmed exons will allow us to validate the exist-
ence of putative gene content. The ability to treat exons as
independent objects provides the opportunity to monitor
changes in the patterns of expression at the exon level allow-
ing for detection and quantification of alterations in exon
usage and changes in alternative splicing patterns. The designhttp://genomebiology.com/2007/8/4/R64 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. R64.3
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dramatically increases the resolution of whole genome gene
expression analysis down to the level of transcript diversity.
The design objective was to include a probeset for every
potential exon in the entire human genome. We used a wide
variety of predicted and empirically identified transcript/
exon collections as input for the probe design algorithms. The
collections include Ensembl [26], GenScan [27], Twinscan
[28], SLAM [29], as well as direct alignment of cDNA-based
content, such as RefSeq mRNAs [30], GenBank mRNAs, and
dbESTs. The various input sequences and annotations were
consolidated and projected onto the November 2002 (hg13)
assembly of the human genome and parsed into unique probe
selection regions (PSRs) as defined by the edges of the projec-
tions (Figure 1). Across the genome, more than one million
exon clusters were identified and grouped into transcript
clusters based on overlapping boundaries of input annota-
tions. During the probe selection process, the best four 25-
mer probes for expression level analysis were selected from
each probe selection region [31]. The median size of all PSRs
was 119 base-pairs (bp). Approximately 90% of all PSRs were
covered by 4 probe pairs. Any PSR of length greater than or
equal to 17 nucleotides (nt) received at least 1 probe pair. Pilot
experiments suggested that some signal intensity could be
achieved from hybridization to a contiguous perfect match of
17 or more nucleotides. Probes for PSRs that were less than 25
nt were designed with a central target sequence and sur-
rounding genomic sequences filling out the 25-mer. Each
probe pair consists of a perfect match probe and a mismatch
probe that has a one base substitution in the middle position.
The final design included 1.4 million PSRs and more than 9.6
million unique probes that were manufactured onto four 12.8
mm2 arrays with 8 micron feature pitch.
The design was also intended to take alternative 5' or 3' splice
sites into consideration. If there was sequence evidence of
overlapping exons with different edges (suggesting alterna-
tive donor or acceptor sites), then that exon was divided into
multiple PSRs. In doing so, the array should be able to detect
changes in splice site usage in addition to monitoring inclu-
sion level of the exon as a whole. The PSR size for alternative
splice sites is still constrained by the 17 bp minimum. Conse-
quently, splice sites that are shifted by less than 17 nt were not
included in the design.
For this design we intentionally omitted exon-exon junction
probes. While junction probes provide additional informa-
tion about the possible splice variants present, they require a
priori knowledge of those variants. Junction designs are typ-
ically dependent on observed junctions and we surmised that
even the best enumeration of splice variants to date is sub-
stantially incomplete and may introduce an undesired bias
into our design. A summary of the chip design details is
included in Additional data file 7.
Determination of detection above background
With only four probes per probe selection region, standard
methods for establishing if a particular sequence is present or
absent are not effective. As an alternative, we employed a
detection metric that compares the intensity from each per-
Exon microarray design Figure 1
Exon microarray design. Input sequences from a variety of sources were projected onto the November 2002 version of the human genome (hg13). Where 
possible, up to four probe pairs were selected for each PSR. Probesets that overlap Ensembl or RefSeq sequences are labeled 'Supported.' Probesets that 
fall within the genomic boundaries of a transcript cluster are labeled 'Bounded.'
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EST
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Probes
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fect match probe to a distribution of background probes with
similar GC content (Figure 2a). The resulting metric provides
a probability that the signal intensity value is part of the back-
ground noise (see Materials and methods for details). Thus,
probes with low p values have signals that are distinct from
Determination of detection above background Figure 2
Determination of detection above background. To determine if a given probe signal is detected above background, the PM intensity is compared to a 
distribution of background probes with the same G/C content. A p value is calculated representing the probability that the signal intensity is part of the null 
distribution. Probes with DABG p values of less than 0.05 are considered to be detected above background. For this study, the mismatch probes from 
PSRs supported solely by GenScan Suboptimal predictions were used to create the null distributions. (a) Diagram depicting the comparison of background 
signal to PM signal. PM signal intensities at the 95% of background probes with the same GC content are given a p value of 0.05. (b) ROC curve of the 
median DABG p value from all 48 samples. The area under the curve (AUC) is used as a measure of ability of the metric to differentiate between 
expressed and non-expressed sequences. The sensitivity and specificity values are shown for a DABG p value cutoff of 0.05. (c) Table of the median 
sensitivity and specificity values for each tissue using a DABG p value cutoff of 0.05.
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(Median values across all 48 samples)
AUC = 0.920
(a)
(b) (c)
Cerebellum 0.795 0.802
Corpus callosum 0.854 0.830
Frontal lobe 0.886 0.811
Occipital lobe 0.896 0.842
Parietal lobe 0.913 0.840
Temporal lobe 0.860 0.890
Spinal cord 0.901 0.765
Adipose 0.880 0.802
Appendix 0.809 0.834
Heart 0.886 0.827
Kidney 0.846 0.867
Liver 0.872 0.746
Ovary 0.898 0.683
Skeletal muscle 0.835 0.893
Stomach 0.854 0.863
Testis 0.925 0.685
Tissue Median
sensitivity
Median
specificity
Median ROC plot values
for DABG P value = 0.05
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background and, therefore, considered to be detected above
background (DABG).
We employed a receiver operating characteristic (ROC) curve
to evaluate the performance of the DABG algorithm. The
array design contains exon and intron probesets for a set of 71
housekeeping genes that were previously determined to have
constitutive expression across a broad range of tissue samples
(see Additional data file 11 for a list of housekeeping genes
used). For the purpose of this analysis, we assumed the exons
to be present and the introns to be absent. We then evaluated
the ability of the DABG metric to separate the control
expressed and non-expressed probesets by determining the
sensitivity (true positive rate) and specificity (false positive
rate) for various DABG p value cutoffs. The resulting curve
using the median DABG p values from all 48 samples is pre-
sented in Figure 2b. Using a cutoff p value of 0.05, we achieve
a median sensitivity of 0.88 (standard deviation (SD) = 0.05)
and specificity of 0.82 (SD = 0.07). This value is also nearly
optimal for the minimization of type I and type II errors (false
positives and false negatives). The median sensitivity and
specificity for each of the tissues is shown in Figure 2c.
Data from tissues
To gain a better understanding of the level of transcript vari-
ation among normal adult tissues, we generated labeled
cDNA target using total RNA from three biological replicates
of sixteen different human tissues (see Materials and meth-
ods for details). The tissues included cerebellum, corpus cal-
losum, frontal lobe, occipital lobe, parietal lobe, temporal
lobe, spinal cord, adipose, appendix, heart, kidney, liver,
ovary, skeletal muscle, stomach, and testis. Additional infor-
mation on the human tissue RNAs is included in Additional
data file 8. The majority of Ensembl/RefSeq supported
probesets (74.1%) are detected above background (DABG p
value < 0.05; see Materials and methods for details) in at least
one of the 16 tissues. Interestingly, Figure 3a shows that
approximately one-third of probesets outside of well anno-
tated exons (bounded) or outside of annotated genes (nei-
ther) are detected in at least one of the sixteen tissues. This
supports conclusions by others [20,21] that there is a large
amount of transcription that occurs outside of annotated
genes and also suggests that there is a significant amount of
transcript diversity that is missed in the set of curated genes.
Figure 3b shows that in an average tissue, approximately 40%
of probesets supported by mRNA sequences or the curated
Ensgene set are detected. Gene prediction algorithms that
incorporate homology to the mouse genome also have a high
rate of detected probesets. Interestingly, nearly 10% of
probesets (more than 52,000 per tissue) that are supported
only by the prediction algorithms (Genscan, Genscan Subop-
timal, Twinscan, SLAM) are detected in an average tissue.
The total fraction of probesets present in at least one of the
tissues is likely to be higher. The vast majority of probesets
(approximately 833,000 of 1,360,000) are supported by only
one type of evidence. The inclusive nature of the design
results in the majority of probesets being designed to detect
speculative content, sequences that do not overlap a well
annotated exon. As shown in Figure 3c, of these only 12% are
detected, on average. Not surprisingly, the average percent
detected number increases as you increase the number of
types of evidence per probesets to a maximum of just over
50% for 7 or more types of support evidence (Figure 3c).
There is a fair amount of variability in the total number of
probesets detected in each of the tissues. Skeletal muscle,
stomach, and heart express the smallest number of probesets,
while testis, ovary, liver, and several brain tissues express the
largest number (Figure 3d). As expected, the patterns are very
much the same when you look at number of transcript clus-
ters (genes) expressed (Figure 3e). With more than 1.36 mil-
lion probesets on the array, the total number of probesets
considered to be detected above background by chance is
large. At a p value of 0.05, the expected number of false posi-
t i v e s  w i t h  1 . 3 6  m i l l i o n  m e a s u r e m e n t s  i s  a p p r o x i m a t e l y
68,000. However, when you require the probeset to be
detected in all 3 replicates of a tissue, the chances of random
detection is dramatically reduced, with only about 170
expected false positives.
In Figure 3f, testis and brain are shown to have a large
number of probesets that are tissue-specific; probesets
expressed in that tissue and not in any other tissue. These tis-
sue-specific probesets may be from genes that are only
expressed in a single tissue, or individual exons that are
included in a tissue-specific fashion via alternative splicing.
This result is consistent with studies using EST sequences to
predict tissue-specific splicing events. Yeo and colleagues
[10] found that brain, liver, and testis had the highest number
of alternative splicing events using a method that normalizes
the number of observed alternative splicing events to the EST
coverage in each tissue. Because the various sub-regions of
the brain tend to have highly similar splicing and expression
patterns, we grouped all of the brain tissues together to iden-
tify probesets that are unique to the brain as a whole. This is
likely to be an over-simplification and we still expect differ-
ences in expression and splicing patterns of the various sub-
regions. However, grouping the brain tissues together
increases the statistical power to identify genes and individ-
ual exons that are enriched in the brain as a whole. Previous
studies have shown that the brain itself is very different from
other tissues and rich in transcript diversity [10,24,25]. It
should be pointed out that the RNA samples are extracted
from gross tissue dissections and are likely to contain a mix-
ture of distinct cell types. Expression and splicing patterns
are likely to be different between cell types and possibly from
cell to cell within the same type. All of this diversity becomes
part of the biological noise in the experiment. Our approach
should allow us to discover gross relative exon-level changes
that are significantly different between one or more tissues.R64.6 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. http://genomebiology.com/2007/8/4/R64
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Probeset and transcript cluster detection Figure 3
Probeset and transcript cluster detection. (a) Bounded, supported, and probesets that fit into neither category are binned by the number of tissues the 
probeset is detected in. For this and all further analyses, a probeset must have a DABG p value less than 0.05 in all 3 biological replicates of a tissue to be 
considered detected. (b) Total number and number of detected probesets listed by evidence type. One probeset may fall into more than one category. 
Percent detected value is the average detection rate across the 16 tissues. (c) Total number and number of detected probesets listed by number of types 
of evidence. Percent detected value is the average detection rate across the 16 tissues. (d) Total number of probesets detected in each tissue. (e) Total 
number of transcript clusters detected in each tissue. For a transcript cluster to be considered detected, a minimum of 50% of Ensembl/RefSeq supported 
probesets must have DABG p values less than 0.05 for at least 2 of 3 replicates. (f) Probesets expressed in only one tissue. To be counted a probeset must 
be detected in all three replicates and not in all three replicates of any other tissue. The 'brain' category represents probesets detected in all three 
replicates of at least one of the six brain tissues and detected in all three replicates of any non-brain tissues (excluding spinal cord).
Number of tissues the probeset is "detected" in
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Identification of tissue-specific exons using the Splicing 
Index
The array design essentially considers individual exons or
parts of exons as independent elements. In theory, this ena-
bles a finer resolution view of the transcriptome, using the
exon as the fundamental unit rather than the gene. However,
it is not possible to use probeset intensities by themselves to
find alternatively spliced exons. This is because an alteration
in the overall transcription or decay rate of a gene will cause
the intensity of all expressed probesets belonging to that gene
to change. Ultimately, the goal is to find changes in exon
inclusion level that are relative to the expression of the gene.
The concept is similar to the indexes used previously to deter-
mine splicing efficiency in yeast [13]. By dividing the intensity
value of a probeset by an estimate of the expression level of
the transcript cluster that the probeset belongs to (Figure 4a),
you create a gene-level-normalized intensity that can be com-
pared between samples. Changes in this value between tis-
sues provide a quantitative measure of exon level relative to
gene level. Alterations signify changes in exon inclusion rate
that may be due to alternative splicing. We refer to compari-
sons of gene-level-normalized exon expression values as the
'Splicing Index' [32]. A similar approach used in conjunction
with a custom exon-junction microarray successfully identi-
fied a number of splicing events implicated in breast cancer
[33].
Because a consistent gene-level estimate is important to the
Splicing Index algorithm, we tested the robustness of the
gene-level estimation method to changes in alternative splic-
ing. We simulated exon skipping events by systematically
substituting the intensity value of probesets used in the gene-
level estimate with the background intensity and re-calculat-
ing the gene-level estimate. We then determined the median
percent deviation from the original gene-level estimate for
every transcript cluster in each of the tissue samples. Using
the median intensity of all Ensembl/RefSeq supported
probesets as the gene-level estimate proved to be fairly robust
to our simulated alternative splicing. Transcript clusters with
increased numbers of probesets used in the gene-level
estimation tended to have smaller percent deviations. For
transcript clusters with 5 or more probesets, 80% of the
measurements had median deviations of 26% or less. The
median deviations were 18% and 11%, respectively, for tran-
script clusters with 10 or more and 20 or more probesets used
Splicing Index Figure 4
Splicing Index. (a) Splicing Index equations. (b) PHLDB1: brain-specific Splicing Index values graphed for all Ensembl/RefSeq supported probesets and RT-
PCR validation using primers in flanking exons. (c) SLC9A7: graphed as in (b).
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in the gene-level estimation. These data are presented in
Additional data file 6.
Exons that are enriched or depleted in one tissue (or group of
tissues) compared to another can be identified by looking for
a divergence in the gene-level-normalized probeset intensity
values. For instance, the brain-specific Splicing Index is cal-
culated by taking the log ratio (base 2) of the median gene-
level-normalized intensity of the 18 brain samples (6 tissues,
3 replicates each) and the median gene-level-normalized
intensity of the 27 non-brain samples (9 tissues, 3 replicates
each). The equation is shown in Figure 4a. The spinal cord
samples were excluded from the analysis because previous
data had shown spinal cord to have a mixture of brain and
non-brain splicing patterns. This value can be calculated for
every probeset that maps to or within a transcript cluster.
Two examples are shown in Figure 4b,c. A brain-specific
Splicing Index value of 0 indicates that the PSR is present at
equal levels in both the brain and non-brain tissues. A posi-
tive value implies elevated exon inclusion in brain, and a
negative value suggests increased skipping of the exon in
brain. In Figure 4b, the majority of exons in the PHLDB1 gene
are present in both brain and non-brain tissues at roughly
equal levels. The spike in index value for the PSR representing
exon 24 suggests that this exon is enriched in brain, with an
average inclusion rate more than 10-fold higher in the brain
tissues. RT-PCR validates the brain-specific inclusion of exon
24 (Figure 4b). The opposite is true for the SLC9A7 gene in
Figure 4c. Inclusion of the region representing exon 13 is sig-
nificantly lower in the brain tissues relative to non-brain
while most other PSRs have approximately equivalent inclu-
sion levels. Again, RT-PCR verifies that skipping of exon 13 is
prevalent in the six brain tissues (Figure 4c).
We used the Splicing Index to identify PSRs that are enriched
in the brain. To find statistically significant probesets we car-
ried out a Student t-test using the gene-level-normalized
probeset intensities comparing the brain tissues as a group to
the non-brain tissues. Genes or probesets that have low
expression level and, therefore, signal intensities that are in
the noise can have a confounding effect on any large-scale
automated analysis. Thus, we filtered our results to exclude
genes and/or probesets that are not expressed. In order for a
transcript cluster to be included in the analysis, we required
that at least 50% of the well annotated exons (Ensembl/Ref-
Seq supported probesets) were detected above background
(DABG p value < 0.05) in more than half of the samples in
RT-PCR validation of brain-enriched exons identified by the Splicing Index algorithm Figure 5
RT-PCR validation of brain-enriched exons identified by the Splicing Index algorithm. Approximately 15 μl of PCR product were separated on a 2.5% 
agarose gel stained with ethidium bromide. Primers are designed to well annotated exons that flank the PSR identified as brain enriched by the Splicing 
Index. Primer sequences are available in Additional data file 9.
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each group. In addition, we required that any single probeset
be detected (DABG p value < 0.05) in more than one half of
the samples in at least one of the two groups. We used the
Benjamini-Hochberg method of multiple testing correction
[34,35]. Utilizing a false discovery rate of 0.05 resulted in a p
value cut-off of 0.012.
While critical for discovery of novel splicing events, the large
number of speculative probesets on the array necessitates
careful filtering to reduce potential false positives. In the
interest of enriching the dataset for true positives, the Splic-
ing Index results were further filtered to remove probesets
with the highest likelihood of introducing false positives.
Probesets that mapped to multiple genomic locations were
discarded (approximately 6.8% of probesets). Probesets with
intensity values that were highly discordant with the gene
expression level (probesets with intensities greater than ten-
fold higher than the median intensity of Ensembl/RefSeq
supported probesets) were likewise rejected. In addition,
genes with greater than ten-fold changes in average expres-
sion level between the brain and non-brain tissue groups were
also removed. Despite the fact that the Splicing Index
approach is designed to mitigate differences in gene expres-
sion level, previous experience has shown that very large dif-
ferences in gene expression level can amplify the noise
leading to potential false positives. After filtering, 10,148
probesets with statistically significant differences in gene-
level normalized intensities between the brain and non-brain
tissues remained. Of these, 2,161 are indicated as being
enriched in the brain tissues relative to non-brain tissues.
These 2,161 probesets from 1,097 transcript clusters (genes)
represent potential differentially alternatively spliced
regions.
Experimental validation of predicted brain-enriched 
exons
RT-PCR validation of the increased inclusion in the brain tis-
sues of several of the identified probesets is shown in Figure
5. In order to evaluate the performance of the Splicing Index
algorithm for identifying differentially regulated, tissue-spe-
cific splicing events from the exon array data, we systemati-
cally tested the top hits sorted either by t-test  p  value or
magnitude of change. For simplicity, we focused our valida-
tion efforts on internal alternative splicing events that could
be tested using primers in constitutive exons flanking the
identified probeset. Therefore, probesets at the extreme edges
of transcript clusters and probesets mapping to annotated
alternative transcriptional start sites, alternative 3' terminal
exons, or alternative polyadenylation regions were not tested.
Finally, the Splicing Index results were manually filtered by
BLATing [36] the probeset sequence to the UCSC Genome
Browser [37]. By observing the probeset location in genomic
context we were able to remove probesets with ambiguous
transcript cluster assignment and probesets within regions of
overlapping transcription units.
After filtering, the 32 probesets with the most significant p
values were tested by RT-PCR. Of the 32 probesets, 27
(84.4%) showed clear enrichment in the brain tissues by RT-
PCR using primers in flanking exons. The higher molecular
weight band present in the six brain tissues indicates inclu-
sion of additional sequence in the mRNAs expressed in those
tissues via alternative splicing. In nearly all cases, the size dif-
ference between the skip and include products is identical to
the size of the exon that the identified probeset was designed
to detect. A commonly observed artifact for RT-PCR products
of alternatively spliced regions is visible on several of the gels.
This intermediately sized band typically migrating just below
the larger of the two isoforms represents a heteroduplex of
the two alternatively spliced forms [38,39]. All RT-PCR gels
not present in Figure 5 are shown in Additional data file 4. We
also carried out RT-PCR on the probesets with the largest
magnitude change of gene-level normalized intensity. Of the
top 23, 21 (91.3%) probesets demonstrated clear patterns of
brain-specific alternative splicing. Altogether, a total of 84
predicted tissue-enriched probesets identified by the Splicing
Index have been evaluated in the course of this project with a
86% (72/84) validation rate.
Discovery of novel brain-enriched exons
Among the 2,161 probesets identified as brain-enriched by
the Splicing Index, 287 of them were supported only by exon
predictions (Genscan, Genscan Suboptimal, Twinscan,
SLAM). Inclusion of these exons in transcripts produced in
the brain would represent novel splicing events since neither
the exons themselves nor the splicing events involving the
exons have been observed in publicly available cDNA
sequences. Several potential novel brain-enriched exons were
selected and inclusion of these exons in the brain was verified
by cloning and sequencing RT-PCR products from one or
more brain tissues. RT-PCR using primers in known exons
that surround the predicted exons for several of these genes is
shown in Figure 5.
In Figure 6, the sequences of RT-PCR products for the WNK1
gene shows the inclusion of two novel exons in the brain tis-
sues. The sequences were BLATed [36] to the human genome
and displayed in the UCSC Human Genome Browser [37].
The newly identified exons do not overlap any mRNA or EST
sequences. Probesets were designed because the exons were
predicted from one of the in silico gene finding algorithms. As
can been seen near the bottom of Figure 6b in the conserva-
tion tract, the sequences of the exons themselves are well con-
served in a variety of other organisms. As has been seen for
many regulated alternatively spliced exons, the sequence sim-
ilarity extends into the surrounding intron, suggesting possi-
ble conservation of a shared regulatory element [40-42]. This
also highlights the value of sequence conservation in
identifying exons and regulatory motifs using sequence infor-
mation alone.R64.10 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. http://genomebiology.com/2007/8/4/R64
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Discovery of novel exons Figure 6
Discovery of novel exons. (a) RT-PCR validation of predicted brain-enriched exons. (b) Sequences of RT-PCR products from parietal lobe RNA aligned 
to the human genome using the BLAT tool [36] available on the UCSC Genome Browser website [53].
C
e
r
e
b
e
l
l
u
m
F
r
o
n
t
a
l
 
l
o
b
e
O
c
c
i
p
i
t
a
l
 
l
o
b
e
T
e
m
p
o
r
a
l
 
l
o
b
e
A
d
i
p
o
s
e
A
p
p
e
n
d
i
x
H
e
a
r
t
K
i
d
n
e
y
L
i
v
e
r
O
v
a
r
y
S
k
e
l
e
t
a
l
 
m
u
s
c
l
e
S
p
i
n
a
l
 
c
o
r
d
S
t
o
m
a
c
h
T
e
s
t
i
s
C
o
r
p
u
s
 
c
a
l
l
o
s
u
m
P
a
r
i
e
t
a
l
 
l
o
b
e
WNK1
(a)
(b)http://genomebiology.com/2007/8/4/R64 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. R64.11
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R64
Altogether, our initial, exploratory analysis revealed 17 novel
exons in 11 genes. In addition, six new alternative splicing
patterns involving annotated exons were discovered during
the RT-PCR validation process. These six new splicing events
include four instances of novel arrangements of annotated
exons, one new alternative 5' splice site and one new alterna-
tive 3' splice site (see Additional data file 9 for details). The
sequences of the novel exons and new alternative splicing
events have been deposited in GenBank (Gen-
Bank:DQ925667-DQ925693 and GenBank:EF139845-
EF139860). Information on the novel exons, including RT-
PCR primer sequences can be found in Additional data file 9.
In addition, RT-PCR gels for all other novel exons not
included in Figure 5 are included in Additional data files 1 and
4. These data demonstrate the ability of an inclusive exon
array design to discover novel exons and novel alternative
splicing events. It also suggests that the catalog of splicing
events in publicly available sequences is far from complete.
Estimates of the frequency of alternative splicing
To estimate the frequency of alternative splicing among our
set of normal adult human tissues, we compared each tissue
to every other tissue. In all, 120 pair-wise comparisons were
carried out among the 16 tissues. Gene-level normalized
intensities were calculated for each probeset that fell within
the bounds of a transcript cluster. The values from three bio-
logical replicates of one tissue were compared to the three
biological replicates of another tissue using a Student t-test.
To reduce the number of false positives, we filtered out non-
expressed genes by requiring that a given transcript cluster be
'detected' in at least two of the three replicates in each tissue.
A gene is considered present if more than half of the Refseq/
Ensembl supported probesets were detected above back-
ground with a p  v a l u e  o f  0 . 0 5  o r  l e s s .  I n  a d d i t i o n ,  e a c h
probeset must be detected above background (DABG p value
≤ 0.05) to be included in that particular pair-wise compari-
son. Filtering steps similar to those used in the selection of
brain-enriched PSRs were also employed to remove potential
cross-hybridizing probesets and genes with greater than ten-
fold differences in gene-expression level. It should be noted
that for alternative splicing to be detected by the Splicing
Index algorithm, the splicing pattern must change between
tissues. For example, a gene that expresses multiple isoforms
in the same proportion in each tissue tested will not be
detected as differential alternative splicing.
A total of 19,221 transcript clusters ('genes') were used as
input to the analysis. Of these, 12,139 were detected in a min-
imum of two tissues. There were 8,837 transcript clusters that
had at least one probeset with a Splicing Index t-test p value
of less than 0.001 and minimum magnitude of change greater
than 0.5, suggesting differential exon usage in at least one
comparison. This means that 72.8% (8,837/12,139) of
detected genes displayed evidence of differential alternative
splicing among the 16 normal adult human tissues. Addi-
tional data file 2 contains details on the number of probesets
identified as differentially expressed in each of the pair-wise
tissue comparisons.
In an effort to demonstrate the validity of the pair-wise com-
parison approach, we calculated the frequency that the RT-
PCR validated brain-enriched probesets were identified in
comparisons of a single brain tissue (three biological repli-
cates) with a single non-brain tissue (three biological repli-
cates). For each probeset, there were a total of 54 possible
'brain versus non-brain' comparisons, 36 possible 'non-brain
versus non-brain' comparisons and 15 possible 'brain versus
brain' comparisons considered in this analysis (comparisons
involving spinal cord were excluded from the analysis). Using
the same criteria as above, if the gene was not detected in both
tissues, that particular comparison was excluded from con-
sideration. Employing a minimum fold change of 0.5 and t-
test p value of less than 0.01, the median frequency of identi-
fication in single brain tissues versus one non-brain tissue
was 62.7%. This is relative to a median frequency of 11.1% of
single non-brain tissues compared to another single non-
brain tissue and a median frequency of 0% of a single brain
tissue compared to another single brain tissue. Because many
of the identified brain-enriched exons are not completely
unique to the brain, we did not expect to identify our vali-
dated brain-enriched probesets in 100% of the 'brain versus
non-brain' comparisons. These results demonstrate that the
single tissue pair-wise comparison approach can detect the
majority of validated brain-enriched probesets. In addition,
the data verifies the brain-enrichment of these probesets and
suggests that the set of splicing patterns of these identified
exons is fairly consistent across multiple sub-regions of the
central nervous system.
The RT-PCR validation focused primarily on cassette exons,
but the exon microarray is also designed to detect the usage of
alternative 5' and 3' splice sites. Thus, to get a sense of the fre-
quency of alternative splice site usage we calculated the Pear-
son correlation coefficient of signal intensities across the 16
tissues for probesets belonging to the same exon cluster. A
total of 277,838 (26.9%) exon clusters have more than one
probeset. For simplicity, our analysis considered only
Ensembl/RefSeq supported probesets that were expressed in
more than 50% of the tissues. Probesets from the same exon
cluster generally had very high correlation with a median of
0.83. This is relative to a median correlation of -0.01 for
probesets selected randomly from 2 different exon clusters
(Additional data file 5). Approximately 21% of exon clusters
had correlation values less than 0.5. While this is not a direct
measure of the frequency of alternative 5' and 3' splice site
usage, it does provide a sense of how often probesets from the
same exon cluster are divergent, which may be due to alterna-
tive splice site usage.R64.12 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. http://genomebiology.com/2007/8/4/R64
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Discussion
Due to the inclusive nature of our genome-wide exon micro-
arrays, we are able to discover novel alternative splicing pat-
terns in addition to monitoring known splicing events. As
technology allows for smaller feature sizes, it will be possible
to include larger numbers of probes per array, thereby
increasing the feasibility of large-scale non-biased designs.
Microarray designs that are more inclusive and less depend-
ent on current genome annotations will ultimately aid in the
development of tools that are designed to annotate, rather
than the other way around. For example, recent work using a
similar design concept based on the mouse genome was able
to refine gene boundaries using co-regulation of exons across
many different tissue types [43]. However, our data suggest
that there is a large amount of expression outside of well
annotated exons. Reliance on any one single exon prediction
algorithm or sequence content source will likely result in
incomplete coverage.
Exon microarrays represent a huge step forward in the reso-
lution level of gene study. The tool makes it possible to use the
entire genome as a splicing reporter. Future studies using this
technology should aid in the discovery of splicing regulatory
mechanisms and expand our knowledge of how alternative
splicing is controlled. In addition to splicing information, the
exon array format provides excellent coverage at the gene
level. With more than 40 individual probes for the average
gene, robust gene-level expression estimates are likely to be
more sensitive than array designs with fewer probes per gene.
We have demonstrated the use of a simple and easy to imple-
ment algorithm for finding changes in alternative splicing
patterns from exon array data. While there are more sophis-
ticated techniques for finding splicing patterns from microar-
ray data [16,44,45], the Splicing Index [32] was intended to
be a straightforward example of a method for identifying
tissue-specific exons. The method combined with standard
statistical tests is robust and was able to identify known
brain-specific splicing patterns. In addition, we discovered
novel exons involved in alternative splicing events regulated
in a brain-specific pattern. Our data suggest that a significant
proportion of isoforms is yet to be discovered and may indi-
cate that the frequency of alternative splicing based on cDNA
sequences is an underestimate. In fact, pair-wise compari-
sons of the 16 tissues suggest that nearly three-quarters of
genes are differentially alternatively spliced. This value is very
close to other estimates of the frequency of alternative splic-
ing based on microarray experiments [7]. However, our esti-
mation is potentially an underestimate of the total amount of
alternative splicing since our tissue set is limited and did not
include any samples from fetal or diseased tissues.
By using a strict set of filtering criteria and by employing a
manual filter by which the data for potential validation tar-
gets were observed in a genomic context, we were able to limit
the number of false positives. The RT-PCR validation rate for
all splicing events examined in this study was approximately
86%. Many of the validation targets mapped to exons that
were previously known to be alternatively spliced based on
sequence information from the UCSC Genome Browser and
validation rates for probesets mapping to these events was the
highest. Approximately 98% (46/47) of annotated alternative
splicing events highlighted by the Splicing Index showed clear
enrichment of the queried exon by RT-PCR. This situation is
a more appropriate comparison to many exon-junction arrays
since the designs are already filtered for known splicing
events [14,33,45-47]. The validation rate for the purely novel
exons was considerably lower, with 11 of 16 targets (69%) val-
idated by RT-PCR. A negative RT-PCR result, however, does
not necessarily mean that the identified probeset is a false
positive. It only signifies that the exon is not included in a
transcript that contains the exons to which the primers were
designed. The sequence may still be expressed as an inde-
pendent transcript or in a splice variant that does not include
the flanking primer exons. This may be more likely in the case
of potential novel exons that are only predictions or have min-
imal sequence support since designing primers for these
sequences is problematic. Probesets with splicing index t-test
p values as high as 2.5 × 10-4 and splicing index values as low
as 0.6 still gave positive validation results by RT-PCR. In
many cases, the exons overlapping those probesets had less
dramatic splicing pattern changes or identified exons that
were not completely unique to brain. The high validation rate
clearly demonstrates the ability of the Splicing Index algo-
rithm to identify exons that are significantly enriched in one
tissue or a group of tissues relative to another.
While microarray designs that include exon-exon junctions
do provide an additional bit of information about how exons
are joined together, the design is not optimal for discovery of
new splicing events. Johnson and colleagues [7] were able to
detect new exon skipping events by utilizing a human exon
junction microarray. However, their approach is not capable
of detecting new splicing events involving novel exons since
their microarray was designed solely on observed junctions in
RefSeq mRNA sequences, which do not comprise a complete
enumeration of splice variants. Exon and junction type array
designs each have their pros and cons. A combination of both
approaches may provide additional power in the study of
alternative splicing. Even our set of predicted exons is likely
to be incomplete. Small exons that are less than 17 bp, for
example, are not included in our design. It is also possible for
an exon to be missed if it was not predicted by any of the
design inputs or if the PSR sequence itself was not amenable
to designing an acceptable probe. The design was, however,
intended to be as inclusive as possible. It represents an
improvement of more than an order of magnitude in genome
coverage over currently available tools.
To date, most microarray-based target discovery programs in
the pharmaceutical industry have been limited to looking at a
single version of a transcript. We did a cursory analysis of thehttp://genomebiology.com/2007/8/4/R64 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. R64.13
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number of potential drug targets that exhibit potential tissue-
specific alternative splicing patterns. Nearly all small-mole-
cule drug targets fall into 130 InterPro domain protein fami-
lies [48]; 3,365 genes (transcript clusters) containing one of
these protein domains were identified. These 3,365 genes
nominally represent the 'drugable genome.' Approximately
77% of detected genes from this group show evidence of alter-
native splicing in our pair-wise comparison of 16 normal
adult human tissues. Additional data file 3 shows that differ-
ent classes of drugable genes display variable amounts of dif-
ferential alternative splicing. For example, the data suggest
that nearly 85% of detected serine/threonine protein kinase
genes may be differentially alternatively spliced. The largest
class of genes is the Rhodopsin-like GPCR with more than
600 members. Likely due to their low expression levels, only
about 150 of these genes are detected among the 16 tissues.
And of those, only about a third present evidence of differen-
tial alternative splicing (Additional data file 3). Overall, the
high percentage of drugable genes with potential tissue-spe-
cific isoforms may represent an untapped source of informa-
tion that could benefit drug discovery programs.
Using the exon microarray technology, we will be able to
measure changes in the splicing patterns of thousands of
genes at once and discover new patterns of alternative splic-
ing. Given the diversity of transcripts likely to be created from
genes, and the importance of detecting and differentiating
these transcripts for the correct interpretation of biological
systems, we believe our arrays are a useful, enabling tool for
further study. 'Gene expression' is properly becoming 'tran-
script expression.'
Conclusion
In this work we analyzed the expression of more than one mil-
lion individual annotated and predicted exons across three
biological replicates of sixteen normal adult human tissues
using a prototype exon microarray. Our data suggest signifi-
cant expression from regions outside of well annotated exons
and well annotated genes, with nearly one-third of probesets
in these regions detected above background in the average tis-
sue. Using a conceptually simple algorithm called the Splicing
Index that normalizes exon intensity by expression level of
the gene, we identified and validated a number of exons that
were enriched in samples from six sub-regions of the brain
relative to nine non-brain tissues. After rational filtering of
the Splicing Index results, systematic RT-PCR examination of
the top scoring hits resulted in a validation rate of around
86%. Pair-wise comparisons of each of the 16 tissues suggests
that approximately 73% of expressed genes are potentially
differentially alternatively spliced. In addition, we demon-
strate how the inclusive nature of the exon array can identify
novel exons that display tissue-specific splicing patterns. Our
cursory examination validated 17 such novel exons in 11
genes. An additional six examples of new alternative splicing
patterns involving annotated exons were also discovered. The
analysis methods presented here are applicable to a wide
range of microarray designs including exon, junction, and til-
ing arrays. The exon level data generated from the 16 tissues
will likely be a rich source of information for the study of the
regulation of alternative splicing.
Materials and methods
Target preparation and hybridization
Total RNA was purchased from Biochain (Hayward, CA,
USA). RNA samples came from age matched normal human
males (excluding female-specific organs) with three biologi-
cal replicates for each of the 16 tissues. Total RNA (100-200
ng) was reverse transcribed using a random hexamer/T7-pro-
moter oligonucleotide (5'-GAATTGTAATACGACTCACTAT-
AGGGNNNNNN-3') for initial strand priming. Second strand
cDNA was generated using Klenow Fragment (NEB; Ipswich,
MA, USA) and amplified into cRNA by T7 RNA Polymerase-
based IVT (MEGAscript T7, Ambion; Austin, TX, USA).
Resulting cRNA was cleaned up on an RNeasy column (Qia-
gen; Valencia, CA, USA). cRNA was converted back into
cDNA via reverse transcription with random hexamers. The
second strand was generated and cDNA was cleaned up on a
QIAquick PCR Purification column (Qiagen). Double-
stranded cDNA was fragmented with 0.6 U DNaseI
(Promega; Madison, WI, USA) at 37°C for 10 minutes. Frag-
ment size was checked using a Bioanalyzer (Agilent; Santa
Clara, CA, USA) with optimal fragment size in the 50-200 bp
range. Fragmented cDNA was end labeled with a biotin-con-
jugated nucleotide analog (DLR-1a; Affymetrix, Inc.) using
terminal transferase (Roche; Nutley, NJ, USA). Fragmented
and labeled cDNA was hybridized for 16 hours at 50°C in a
hybridization solution containing 7% DMSO. A constant mass
of 20 μg of double-stranded cDNA was hybridized to each
array. One hybridization mixture per sample was hybridized
serially to the four chip set over four consecutive days. After
hybridization, arrays were stained and washed on a GeneChip
Fluidics Station (Affymetrix, Inc.) using standard protocols
for eukaryotic arrays. Additional information on the perform-
ance of the assay can be found online [49].
Data acquisition and analysis
Following staining and washing, the arrays were scanned
using a GeneChip Scanner 3000 (Affymetrix, Inc.). The 8
micron pitch features on the array were scanned at 1.09
micron pixel resolution and probe intensity is reported after
image alignment and gridding using GeneChip Operating
System software (Affymetrix, Inc.). Arrays were normalized
using individual probes from 675 probesets from 71 empiri-
cally derived housekeeping genes shown to be consistently
expressed across many tissues. The median perfect match
(PM) value for this collection of normalization controls is set
to 700 and is used to calculate a scaling factor which is then
applied to all PM and mismatch (MM) probes. These probes
are present on all four chips in the array set. Probeset intensi-
ties were generated from individual PM and single base MMR64.14 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. http://genomebiology.com/2007/8/4/R64
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probes using the simplified expression analysis (SEA)
method. In short, PM intensities are attenuated to reflect the
background as measured by the MM probes. The SEA
probeset value is the median probe intensity using the follow-
ing formula:
U(i,j) = ((pm - mm) + sqrt((pm - mm)^2 + 4 × L × pm × 
mm))/2
We used a value of 0.005 for L, the attenuation term. Addi-
tional information about the SEA algorithm can be found
online [50]. Microarray design information and array data
are available through the NCBI Gene Expression Omnibus
(series accession number GSE5791) [51].
Determination of detection above background
To determine if the signal intensity for a given probe is above
the expected level of background noise, we compared the sig-
nal for each probe to a distribution of signals from probes
with the same GC content that are not expected to detect real
target. For this study, we used the single base mismatch
probes from PSRs that were supported only by Genscan Sub-
optimal predictions. This represented a large group of probes
that were the least likely to detect real target and, therefore,
likely to reflect background signal. We generated a p value
representing the probability that the signal intensity of a
given probe is part of the background distribution (Additional
data file 4). The p value is determined by comparing the PM
intensity for a given probe to the intensity for the group of
background probes with the same GC content. The probes are
ranked by intensity and the p value is calculated by dividing
the rank of the probe by the total number of background
probes in that GC bin. Thus, a probe p value of 0.05 indicates
that the PM intensity is larger than the 95% percentile of the
background probes with the same GC content. Probes with
small p values had signal that was separable from noise and,
therefore, considered to be DABG. The individual p values
from all probes in a probeset were combined using Fisher's
Exact test to generate a p value for the probeset. A probeset
that had a DABG p value of 0.05 or less was considered to be
detected (above background).
RT-PCR and sequence validation
Approximately 2 μg of total RNA was reverse transcribed
using the TaqMan Reverse Transcription Reagents kit per the
manufacturer's instructions (Applied Biosystems; Foster
City, CA, USA). A combination of oligo dT and random hex-
amers were used to prime reverse transcription. PCR primers
were designed in constitutive exons flanking the target
sequence. PCR was carried out using Taq Polymerase
(Promega) per the manufacturer's instructions using approx-
imately 50-100 ng of cDNA as template. PCR products were
separated on 2.5% agarose gels and stained with ethidium
bromide for visualization. Selected RT-PCR products were gel
purified and cloned into a TA Cloning vector (Invitrogen;
Carlsbad, CA, USA) for sequencing. All RT-PCR primer
sequences are included in Additional data file 9.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 provides RT-PCR
results of novel tissue-specific exons. Approximately 15 μl of
PCR product were separated on a 2.5% agarose gel stained
with ethidium bromide. Primers were designed to well anno-
tated exons that flank the PSR identified as a potential novel
tissue-specific exon by the Splicing Index. Primer sequences
are available in Additional data file 9. Additional data file 2
includes pair-wise tissue Splicing Index results. The three
biological replicates of each individual tissue were compared
to each of the other tissues using the Splicing Index algo-
rithm. The Splicing Index compares gene-level normalized
probeset intensities using a Student t-test. (a) The number of
probesets that have significantly different inclusion rates
between the two tissues. Probesets with p values less than
0.05 were considered significant. (b) The number of signifi-
cantly different probesets normalized by the number of genes
used in that comparison. In order for a gene to be included in
each of the pair-wise comparisons, 50% of the Ensembl/Ref-
Seq supported exons were required to have DABG p values
less than 0.05 in a minimum of two out of the three biological
replicates of each tissue in that comparison. In all, 9085 of
12,139 genes (74.8%) showed evidence of differential alterna-
tive splicing in at least one tissue comparison. Additional data
file 3 shows alternative splicing in the drugable genome. The
number of genes, number of detected genes, and number of
genes displaying differential exon expression is graphed for
several of the largest classes of drugable genes. Gene classes
are sorted from left to right by the percentage of genes
exhibiting differential alternative splicing. Additional data
file 4 shows additional RT-PCR of predicted brain-enriched
exons. See Additional data file 1 for details. Sequences of the
primers used in the RT-PCR are available in Additional data
file 10. Additional data file 5 shows the correlation of exon
cluster probeset intensities. (a) A histogram of the Pearson
correlation coefficient of signal intensity across the 16 tissues
for probesets belonging to the same exon cluster and
probesets randomly selected from different exon clusters. (b)
A table showing the median and average correlation and the
total number and percent of exon clusters with correlations
less than different values. Additional data file 6 shows the
robustness analysis of gene-level estimation. The robustness
of the gene-level estimation method to alternative splicing
was analyzed by simulating exon skipping events. The inten-
sity of each probeset that was used in the gene-level estimate
was systematically substituted for the background level and
the gene-level estimate was re-computed. The deviation of the
altered gene-level estimate from the original gene-level esti-
mate was determined for every transcript cluster in each tis-
sue sample. (a) The median percent deviation was calculated
by taking the median of the difference of the altered and thehttp://genomebiology.com/2007/8/4/R64 Genome Biology 2007,     Volume 8, Issue 4, Article R64       Clark et al. R64.15
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original gene-level estimates divided by the original gene-
level estimate all multiplied by 100. (b) A graph illustrating
the median percent deviation of gene-level estimates for tran-
script clusters with 5 or more, 10 or more, and 20 or more
probesets used in the calculation of the gene-level estimate.
Additional data file 7 lists the chip design information. Addi-
tional data file 8 contains RNA sample information. Addi-
tional data file 9 lists the RT-PCR primer sequences.
Additional data file 10 lists additional RT-PCR primers. Addi-
tional data file 11 lists the normalization control genes.
Additional data file 1 RT-PCR results of novel tissue-specific exons Approximately 15 μl of PCR product were separated on a 2.5% aga- rose gel stained with ethidium bromide. Primers were designed to  well annotated exons that flank the PSR identified as a potential  novel tissue-specific exon by the Splicing Index. Primer sequences  are available in Additional data file 9. Click here for file Additional data file 2 Pair-wise tissue Splicing Index results The three biological replicates of each individual tissue were com- pared to each of the other tissues using the Splicing Index algo- rithm. The Splicing Index compares gene-level normalized  probeset intensities using a Student t-test. (a) The number of  probesets that have significantly different inclusion rates between  the two tissues. Probesets with p values less than 0.05 were consid- ered significant. (b) The number of significantly different  probesets normalized by the number of genes used in that compar- ison. In order for a gene to be included in each of the pair-wise com- parisons, 50% of the Ensembl/RefSeq supported exons were  required to have DABG p values less than 0.05 in a minimum of two  out of the three biological replicates of each tissue in that compari- son. In all, 9085 of 12,139 genes (74.8%) showed evidence of differ- ential alternative splicing in at least one tissue comparison. Click here for file Additional data file 3 Alternative splicing in the drugable genome The number of genes, number of detected genes, and number of  genes displaying differential exon expression is graphed for several  of the largest classes of drugable genes. Gene classes are sorted  from left to right by the percentage of genes exhibiting differential  alternative splicing. Click here for file Additional data file 4 Additional RT-PCR of predicted brain-enriched exons See Additional data file 1 for details. Sequences of the primers used  in the RT-PCR are available in Additional data file 10. Click here for file Additional data file 5 Correlation of exon cluster probeset intensities (a) A histogram of the Pearson correlation coefficient of signal  intensity across the 16 tissues for probesets belonging to the same  exon cluster and probesets randomly selected from different exon  clusters. (b) A table showing the median and average correlation  and the total number and percent of exon clusters with correlations  less than different values. Click here for file Additional data file 6 Robustness analysis of gene-level estimation The robustness of the gene-level estimation method to alternative  splicing was analyzed by simulating exon skipping events. The  intensity of each probeset that was used in the gene-level estimate  was systematically substituted for the background level and the  gene-level estimate was re-computed. The deviation of the altered  gene-level estimate from the original gene-level estimate was  determined for every transcript cluster in each tissue sample. (a)  The median percent deviation was calculated by taking the median  of the difference of the altered and the original gene-level estimates  divided by the original gene-level estimate all multiplied by 100.  (b) A graph illustrating the median percent deviation of gene-level  estimates for transcript clusters with 5 or more, 10 or more, and 20  or more probesets used in the calculation of the gene-level  estimate. Click here for file Additional data file 7 Chip design information Chip design information. Click here for file Additional data file 8 RNA sample information RNA sample information. Click here for file Additional data file 9 RT-PCR primer sequences RT-PCR primer sequences. Click here for file Additional data file 10 Additional RT-PCR primers Additional RT-PCR primers. Click here for file Additional data file 11 Normalization control genes Normalization control genes. Click here for file
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